Previous 10 | Next 10 |
2024-01-31 10:00:03 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...
2024-01-30 11:50:46 ET Gainers: Neximmune ( NEXI ) +163% . Pixelworks ( PXLW ) +47% . PepGen ( PEPG ) +37% . Rail Vision Ltd ( RVSN ) +36% . Bit Origin Ltd ( BTOG ) +34% . Vivos Therapeutics ( VVOS ) +32% . GRI Bi...
2024-01-26 09:02:16 ET More on GRI Bio GRI Bio stock slides 9% amid FDA clearance for testing of IPF drug Financial information for GRI Bio Read the full article on Seeking Alpha For further details see: GRI Bio's board OKs 1-for-7 reverse stock split
GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innova...
2023-12-21 17:27:32 ET More on GRI Bio GRI Bio stock slides 9% amid FDA clearance for testing of IPF drug Financial information for GRI Bio For further details see: GRI Bio files to sell common stock, warrants
2023-12-11 10:01:05 ET More on Forward Air Forward Air Is A Buy Despite Its M&A Drama Forward Air Corporation (FWRD) Q3 2023 Earnings Call Transcript For further details see: Forward Air announces 2024 general rate increase
--News Direct-- GRI Bio CEO Marc Hertz joined Steve Darling from Proactive to share news the company has begun patient enrollment in a Phase 2a biomarker study focused on evaluating GRI-0621 as a potential treatment for idiopathic pulmonary fibrosis (IPF). Patient dosing is expected to co...
Clinical development plan potentially leveraging 505(b)(2) regulatory pathway Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival 1 LA JOLLA, CA, Dec. ...
2023-11-27 10:51:53 ET More on GRI Bio Financial information for GRI Bio For further details see: GRI Bio stock slides 9% amid FDA clearance for testing of IPF drug
Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited compliance and ...
News, Short Squeeze, Breakout and More Instantly...
Cohen & Steers Global Realty Majors Company Name:
GRI Stock Symbol:
NYSE Market:
Cohen & Steers Global Realty Majors Website:
Data demonstrates that NKT cells are activated in airways in IPF patients and inhibition of type 1 invariant NKT (iNKT) cell activity can ameliorate bleomycin-induced pulmonary fibrosis in mice Compared to controls, mice treated with GRI-0621 showed histological improvement in fibrotic le...
LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic an...
LA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic an...